Roivant Sciences Ltd.(ROIV)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Roivant Sciences Ltd. (ROIV) over the last 3 months consists of 121 total transactions. Among these, company executives and board members conducted 121 buys (totaling 130,735,568 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 130,735,568 shares, reflecting net buying interest with an estimated net acquisitions value of $2.39B.
121 insider transactions found. Showing 10 of 121 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| SUKHATME MAYUKH | President | 1,000,000 | $34.10 | Jun 26, 2026 |
| VENKER ERIC | President | 200,000 | $6.63 | Jun 24, 2026 |
| VENKER ERIC | President | 200,000 | $0.77 | May 22, 2026 |
| PULIK RICHARD | Chief Financial Officer | 60,644 | $N/A | Apr 20, 2026 |
| HUMES JENNIFER | Officer | 29,173 | $N/A | Apr 20, 2026 |
| VENKER ERIC | Officer | 200,000 | $0.77 | Apr 20, 2026 |
| OREN ILAN | Director | 896 | $N/A | Apr 17, 2026 |
| EPPERLY MELISSA B | Director | 670 | $N/A | Apr 17, 2026 |
| MOMTAZEE JAMES C | Director | 469 | $N/A | Apr 17, 2026 |
| GLINE MATTHEW | Chief Executive Officer | 289,774 | $8.45 | Apr 16, 2026 |